Company Website Contact Information:
Chris Cox 612-239-8601 ccox@ljpc.com Virtual Web Chat: Friday, May 21st, 12pm-4pm CT Click here to join the meeting Saturday, May 22nd, 8am-9am CT Click here to join the meeting | Virtual Exhibit Hall Home La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. https://www.lajollapharmaceutical.com
XERAVA™ (eravacycline) is the first fully synthetic fluorocycline antibacterial approved by the U.S. FDA for the treatment of complicated intra-abdominal infections. www.Xerava.com
GIAPREZA™ (angiotensin II) is approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. www.Giapreza.com
Additional Information Xerava Product Overview Xerava Tetracycline Differentiation Xerava Prescribing Information 2006-2020 If you would like to discuss further please email Chris Cox at ccox@ljpc.com to schedule a meeting. |